Gerotherapeutix

Gerotherapeutix (formerly Senotherapeutix) is a Houston-based biotechnology company focused on developing "gerotherapeutics"—medicines that target the fundamental biological mechanisms of aging to improve healthspan and lifespan. Founded in 2017 by serial entrepreneur Dr. Kevin Slawin, the company operates through three specialized subsidiaries: Eos SENOLYTIX, Perseus SENOLYTIX, and Phoenix SENOLYTIX. Its core technologies include the MitoXcel™ platform, which uses AI-driven peptides to target mitochondrial membrane potential (ΔΨm) to restore mitochondrial function and eliminate senescent cells, and the ApoptiCIDe™ platform, a controllable gene therapy system for purposeful cell elimination. The company's lead clinical candidate, PTC-2105, is a geropeptide being developed for sarcopenia and sarcopenic obesity, with an IND filing expected in 2026. In March 2026, its subsidiary Eos SENOLYTIX announced a definitive merger agreement with Pulmatrix to advance its pipeline as a publicly traded entity (Nasdaq: EOSX).